There has to be a balanced approach, which first satisfies our need for security and at the same time makes sure we allow reasonable access to foreign investors to the United States.
This is a time of transformation for Pfizer and our industry. We are responding directly to the realities of our operating environment as we build value today while aggressively investing in the future.